Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.
Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback